Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials

BackgroundRelapsing multiple sclerosis (RMS) is a chronic, inflammatory disease of the central nervous system. Ublituximab, an anti-CD20 monoclonal antibody (mAb), is indicated for the treatment of RMS. We performed a systematic literature review (SLR) to identify randomized trials reporting the cli...

Descripció completa

Dades bibliogràfiques

Autors principals:	Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Amir Ansaripour, Wallace Brownlee, David Paling, Mehdi Javanbakht
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-12-01
Col·lecció:	Frontiers in Neurology
Matèries:	relapsing multiple sclerosis relapsing-remitting secondary progressive monoclonal antibodies ublituximab systematic review
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fneur.2024.1479476/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!